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The prevalence of atrial fibrillation (AFib) was estimated in 2005 to affect 3.03 million Americans, 
and its impact will rise because AFib prevalence increases with age (Go et al., 2001; Naccareli et al., 
2009).  One study matched a cohort of AFib patients to comparable patients not diagnosed with AFib 
and found that direct medical costs over the next year were $8,705 more for patients with an AFib 
diagnosis (Kim et al., 2011). Many AFib patients typically present at the emergency department (ED) for 
treatment; while patients with severe forms or AFib or comorbidities require hospitalization, patients 
with low or moderate risk AFib are often unnecessarily hospitalized. Furthermore, two-thirds of chronic 
AFib patients return within six months of a prior ED visit or hospitalization (Kim, Hussein et al., 2009), 
and new onset AFib patients who are not adequately treated or trained about their condition after 
leaving the ED may be readmitted in the hospital within a year of their first visit. These resulting 
rehospitalizations increase the cost burden on healthcare payers as well as the patients themselves.   
In an attempt to address these rising costs, healthcare facilities are turning to disease 
management clinics as a way to help AFib patients manage their condition. By educating patients on 
their drugs, treatment regimens, therapy options, and rate and rhythm control strategies, AFib patients 
could be better equipped to maintain their condition from home and reduce the likelihood of future 
hospitalizations or ED visits. These programs have the potential to result in reduced hospital 
expenditures and fewer ED visits. The purpose of this analysis is to evaluate the effectiveness of a 
disease management clinic (the AFib Transitions Clinic) initiated at UNC Hospitals in July 2015 targeting 
low- and moderate-risk AFib patients. In particular, this analysis will estimate how the rate of hospital 
use by AFib patients (either during the initial ED visit or on a return ED visit) was changed by the 






Atrial fibrillation (AFib) is a condition of arrhythmia that affects the atrial chambers of the heart; 
with AFib, the two chambers receiving circulated blood do not pump regularly, resulting in an overall 
rapid and irregular heartbeat for affected patients. The majority of patients with the disease show no 
symptoms, but patients who show symptoms typically present to the ED. Diagnosis requires the use of 
an echocardiogram or other similar machine. AFib has four general categories based on severity, ranging 
from a single episode of paroxysmal AFib (when symptoms last less than 7 days and are self-terminating), 
to the more chronic or unmanaged severity of permanent AFib. Many AFib patients present with other 
chronic conditions, typically hypertensive heart disease, valvular heart disease, coronary heart disease, 
and, most often, heart failure (Krahn et al., 1995, Wong 2000, Cha et a 2004). 
Treatment for AFib often depends on whether the patient has new onset AFib or if the patient 
has been diagnosed previously and treated for AFib (even for paroxysmal AFib). Both new onset and 
chronic AFib patients require access to anticoagulant drugs, and, in many cases, antiarrhythmic drugs 
and rate monitors. Patients and providers are advised to monitor the prescribed medications for their 
safety and efficacy, as well as the patient’s health and functioning status. Many patients will need to 
return to their primary care provider or other clinic to evaluate any progress of the severity of their AFib, 
as well as ensure that the patients are receiving the correct dosage of their medications. 
Disease Management Clinic 
 As our society grows older and the prevalence of chronic conditions increases, hospitals and 
other providing facilities are establishing disease management clinics to address the need for patient 
monitoring and maintenance among those with at least one chronic condition. The idea behind disease 
management clinics and programs is to engage and educate the patient on their primary chronic 
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condition in order to provide more encompassing care and to address the patient and condition beyond 
acute care. A lead provider – typically a physician – would provide the main source of care at the clinic 
and design treatment regimens, while nurses and other mid-level practitioners would provide the 
disease education and self-management techniques, as well as help monitor the patient’s condition and 
treatment adherence. 
While the concept of diseases management has been used for certain conditions in the past, 
hospitals and providers have broadened the scope and availability of these clinics as the system changes 
to emphasize value-based care (Congressional Budget Office, 2004). Though disease management clinics 
are most commonly used for specific conditions such as diabetes and chronic obstructive pulmonary 
disease, some providers are interested in applying the concept to patients with AFib; some evidence 
supports the use of disease management for AFib (Tran et al., 2012). Indeed, even for AFib patients who 
are at high risk for stroke and other associated diseases, a management service where health providers 
oversee patients’ drug dosage and maintenance led to better outcomes at lower cost (Roccaforte et al, 
2005; Sullivan et al., 2006). 
The AFib Transitions Clinic at UNC Hospital 
The AFib Transitions Clinic (or Transitions Clinic) at UNC Hospital is housed under the emergency 
department (ED). Established in July 2015 by Dr. Anil Gehi and a group of providers at UNC Hospitals, the 
Transitions Clinic provides self-management training and techniques to AFib patients in addition to 
prescriptions and treatment regimens.  The theory, based on evidence from similar clinics for other 
chronic diseases, is that if patients are empowered to fully understand their treatment regimens and 
manage their own care as much as they can, they can avoid future hospitalizations and AFib-related 
complications. Furthermore, if ED providers are aware of a disease management clinic targeting AFib 
patients that can enable patients without severe symptoms to better care for themselves, then ED 
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providers would feel more comfortable discharging these AFib patients from the ED and reduce 
unnecessary hospitalizations. Ideally, the clinic will save time and money for both payers, patients, and 
even some providers. Patients will benefit from both reduced health expenditures and increased time at 
home instead of the hospital. 
To be admitted to the Transitions Clinic from the ED, the attending physician has to refer the 
patient after screening for AFib and other health conditions. The Transitions Clinic aims to capture AFib 
patients who can be treated and released from the ED without immediate hospitalization; that is, these 
patients do not have a severe form of AFib and no other comorbidities requiring hospitalization. If 
successful, the AFib Transitions Clinic would also reduce or at least not increase the need for return to 
the ED among these AFib patients. The Transitions Clinic provides referred patients with prescriptions, 
education on self-management techniques and what the treatment regimens require (e.g., how often to 
check on certain metrics), and scheduling of follow-up care. 
The concept of “self-management” has been applied to other chronic conditions besides AFib, 
but the AFib Transitions Clinic represents the first self-management clinic in the UNC Hospital system 
based in Chapel Hill specifically targeting AFib patients (Sease et al., 2013; Dritsaki et al, 2016). Currently, 
the Transitions Clinic in Chapel Hill is a pilot program. Ultimately, the project team wants to establish 
additional AFib Transitions Clinics at other UNC Hospitals facilities and to evaluate the program using a 
randomized trial. 
Research Question, Hypothesis, and Aims 
This study will investigate the effectiveness of the AFib Transitions Clinic at UNC Hospitals, which 
opened in July, 2015.  My goal is to determine if the Transitions Clinic adjusted provider protocol 
regarding AFib diagnoses in the ED resulted in discharges rather than hospitalization and reduced 90-day 
return to the hospital among low- and moderate-risk AFib patients. The outcomes of effect are (1) 
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hospital admission at the index (initial) ED visit and (2) return to the ED within 90 days of the index ED 
visit. My goal is to determine if the clinic provided treatment at a lower burden to patients and society. 
Hospital admissions and ED visits are often reflective of one’s condition and quality of disease 
management. Furthermore, if AFib-related hospitalizations and emergency visits are averted due to 
treatment in the Clinic, then healthcare payers may see cost savings.  However, even if total costs per 
patient are not reduced by the AFib Clinic due to the cost of the clinic, reductions in hospital use can 
avoid unmeasured costs (e.g., anxiety, pain, or suffering) for patients. 
My research consists of two aims: 
Specific Aim 1: Compare characteristics of low/moderate risk patients before and after availability of the 
AFib Clinic in order to describe the clinic’s target population and assess comparability of the comparison 
group selected from patients prior to the implementation of the Transitions Clinic. 
Specific Aim 2: Estimate the differences in hospitalization and 90-day ED visits potentially attributable to 
the Transitions Clinic.  
Hypothesis: The AFib Transitions Clinic will result in fewer hospitalizations at the index ED visit 
and fewer 90-day returns to ED than the usual treatment pathway (as measured by comparing 
comparable patients in the pre- and post-implementation period). 
Study Design and Statistical Methods 
Study Design 
The idea behind the clinic is to reduce the likelihood of inpatient admission for AFib at the time 
of the initial ED visit for AFib patients not requiring hospitalization, as well as future ED visits and 
hospital admissions related to AFib. If the clinic succeeds in empowering patients to manage their care, 
subsequent visits to the emergency department should decline. Figure 1 depicts the possible pathways 
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for patients presenting at the ED.  Patients with uncomplicated AFib (e.g., low or moderate risk) and no 
complicating comorbidities are appropriate for clinic referral.  In the absence of randomization for the 
pilot program, this study will estimate the hospital and subsequent ED use experience of the comparison 
patients using observational data on patients presenting at the ED with AFib prior to and after the clinic 
implementation.  
Figure 1: Conceptual Model for Study Design 
 
I used logistic regressions to assess the characteristics of patients identified both before and 
after the implementation of the clinic as being suitable for the Transitions Clinic as well  as the net 
impact of the clinic on outcomes. The outcomes are: 1) whether the patient was hospitalized at the 
index ED visit; and 2) whether a patient returned to the ED within 90 days of their index visit. All 
measures are calculated beginning with an AFib patient’s index visit at the ED (i.e., low- and moderate-
risk patients whose index ED visit was before the Transition Clinic started will be the comparison 
patients, and patients whose index ED visit was after July 1, 2015 will be the treatment patients).  
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Figure 2 presents a decision tree used to map the patients’ movements through treatment 
pathways and the possible outcomes they experience. In the model, we only consider patients who are 
low- or moderate-risk; that is, AFib patients whose symptoms are not too severe to require 
hospitalization and can theoretically be discharged from the index ED if an ambulatory disease 
management clinic is available. 
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Not Hospitalized 














During Index ED 
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The parameter estimates required for the decision model before and after the AFib Clinic 
implementation include the likelihood of hospitalization at the time of the index ED visit and the 
likelihood of returning to the ED within three months of index visit. 
Data 
I used observations collected by the AFib Transitions Clinic Project team, led by Dr. Anil Gehi and 
Dr. Kevin Biese, identified by whether they arrived before the implementation of the Clinic or after 
implementation. Included patients were identified by the date of their index visit. The pre-
implementation data (index ED visits collected from January 1, 2015, to June 30, 2015) will reflect AFib 
treatment under the usual care pathway, and the post-implementation data (index ED visits collected 
from July 1, 2015, to December 31, 2015) will reflect treatment provided through the AFib Clinic. These 
timeframes are chosen to maximize respective sample sizes. My time horizon requires my focus on the 
patients’ data from their index visit and during the three months following that visit. 
Patients included in this analysis were patients who had a primary diagnosis of atrial fibrillation 
during their index ED visit and were identified through physician review of records to be appropriate for 
the Transitions Clinic (either before or after availability of the Transitions Clinic). Based on these criteria, 
I used 36 observations pre-implementation and 72 observations post-implementation. 
Three outcome measures were analyzed as dependent variables in this analysis: 1) the 
likelihood of a patient being hospitalized during their index ED visit; 2) the likelihood of a patient 
returning to the hospital within 90 days of their index visit; and 3) the patient’s combined ED/hospital 
use. To define combined ED/hospital use, a patient is coded as 1 for the last dependent variable if they 
had been hospitalized during their index ED visit, had returned to the ED within 90 days, and/or had 
been hospitalized on a return visit to the ED. The last dependent variable is used as a reflection of the 
whole patient experience with care; I hypothesized that the Transitions Clinic would reduce the 
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likelihood of index hospitalizations, return visits to the ED, and hospitalization on follow-up, among its 
visitors, since it would be considered an alternative to hospitalization. The key independent variable 
observed was whether the AFib Transitions Clinic was available at the time of the index ED visit. 
Statistical Methods 
The analysis used logistic regressions run in Stata 12. Since this study is observational rather 
than randomized, it is important to control for other patient characteristics that could be associated 
with outcomes.  All regressions controlled for by gender, age, whether the patient was insured by 
Medicare, and average SAF score. Information on other variables that might be associated with outcome 
(including income, marital status, or socio-economic status) were not available. The SAF score measures 
a patient’s severity of AFib symptoms, with a higher number reflecting worse symptoms. This SAF score 
was used as a proxy for case mix in the sample. Equation 1 below displays the regression equation used 
for all dependent variables: 
Eq 1:  𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂𝑂 = 𝛼𝛼 + 𝛽𝛽1𝑇𝑇𝑇𝑇𝑂𝑂𝑇𝑇𝑂𝑂𝑂𝑂𝑂𝑂𝑇𝑇𝑂𝑂 +  𝛽𝛽2𝑆𝑆𝑆𝑆𝑆𝑆 𝑆𝑆𝑂𝑂𝑂𝑂𝑇𝑇𝑂𝑂 +  𝛽𝛽3𝐺𝐺𝑂𝑂𝑇𝑇𝐺𝐺𝑂𝑂𝑇𝑇 +  𝛽𝛽4𝑆𝑆𝐴𝐴𝑂𝑂 +  𝛽𝛽5𝑀𝑀𝑂𝑂𝐺𝐺𝑀𝑀𝑂𝑂𝑇𝑇𝑇𝑇𝑂𝑂 
Results 
 Table 1 displays the descriptive statistics of the independent and dependent variables for the 
comparison and treatment groups. Regarding the independent variables, the two groups are relatively 
comparable across these characteristics, despite differences in group size. None of the independent 
variables are significantly different for comparison versus patients based on bivariate t-tests. The mean 
age of the treatment group is slightly older (66.7 years) versus the comparison group (64.4 years). The 
treatment group has more patients identifying as white or Caucasian (87.3% versus 83.3%), though the 
comparison group has more patients identifying as female (47.2% versus 38.6%). The comparison 
patients have a higher average SAF score, indicating patients with worse AFib symptoms than those 
found in the treatment group. In addition, the comparison group has more patients with a primary 
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diagnosis of AFib on their index ED visit than those in the treatment group. Finally, the treatment group 
had more people covered by Medicare than the comparison group.  Only one patient in the entire 
sample was uninsured, and insurance status was not mutually exclusive (e.g., a patient can list both 
private and Medicare as their primary forms of insurance). 
Table 1: Descriptive Statistics of Comparison and Treatment Groups 
Characteristic Comparison (pre-
period) group (n=36) 
Treatment (post-
period) group (n=69) 
Univariate Test of 
Difference (p-value) 
Average age (SD) 64.4 (16.3) 66.6 (13.9) 0.48 
Female 47.2% 39.1% 0.43 
White/Caucasian 83.3% 88.4% 0.47 
Case Mix Severity - 
Average SAF score (SD) 
2.0 (0.8) 1.8 (1.0) 0.19 
Primary AFib Diagnosis 97.2% 91.3% 0.25 
Medicare 47.2% 59.4% 0.23 
Hospitalized at Index 
ED Visit 
77.7% 30.4% 0.00* 
Returned to Hospital 
Within 90 Days of 
Index ED Visit 
2.8% 14.5% 0.06 
Combined ED/Hospital 
Use 
80.6% 37.7% 0.00* 
 
The treatment and comparison groups are distinctly different when observing the unadjusted 
distributions of the dependent variables. Figure 3 displays the unadjusted outcome results into the 
decision tree shown earlier. These results reflect the pathways for the dependent variables listed in the 
bottom of Table 1. The pre-period group was 47.3 percentage points more likely to be hospitalized 
during their index ED visit than the post-period group (77.7% versus 30.4%). The treatment group 
showed a higher rate of return to the ED within 90 days than did the comparison group (14.5% versus 
13 
 
2.8%), though this difference is not statistically significant. In total, the comparison group had higher 
unadjusted combined hospital/ED use than the treatment group (80.6% versus 37.7%).   
 
Logistic regressions provide adjusted estimates of the differences between the two groups.  
Table 2 uses multivariate logistic regression to assess whether any differences in observed descriptive 
characteristics for the treatment versus comparison groups.  Consistent with the bivariate assessment in 
Table 1, the treatment and comparison groups did not differ significantly on any observed variables.  
However, although not significant, the physician-identified treatment (post-clinic availability) patients 
Figure 3: Decision Tree for Low/Mod AFib Patients who Present to ED
1+ returns 4 of 69
21 of 69 No Returns 17 of 69
n=69 1+ returns 6 of 69
48 of 69 No Returns 42 of 69
#
1+ returns 1 of 36
28 of 36 No Returns 27 of 36
n=36 1+ returns 1 of 36
8 of 36 No Returns 7 of 36
Not Hospitalized 





















were notably less likely to have AFib as a primary diagnosis and more likely to be insured by Medicare 
than were the physician-identified comparison patients.  Therefore, it is important to control for these 
observed characteristics in the outcome analyses.  However, given the relatively small sample size and 
limited time period for the study, these differences may be due to sampling error.   
 
Table 2: Multivariate Analysis of Descriptive Characteristics (n=105) 
Dependent Variable:  Treatment (Index ED visit 
after July 1, 2015) versus Comparison Patient 
Odds Ratio (95% CI) 
Age 0.99 (0.96, 1.04) 
Female 0.74 (0.29, 1.88) 
White/Caucasian 1.49 (0.43, 5.19) 
Case Mix Severity (Average SAF Score) 0.79 (0.49, 1.28) 
AFib Primary Diagnosis 0.29 (0.03, 2.81) 
Insured by Medicare 1.71 (0.56, 5.19) 
Constant 6.72 (0.21, 210.37) 
 
 Table 3 displays the results of the logistic regressions for my three dependent variables. For the 
first dependent variable (whether the patient was hospitalized during their index ED visit), the 
availability of the AFib Transitions Clinic showed a statistically significant protective effect, holding all 
other variables equal (OR=0.13, 95% CI: 0.05, 0.35). In addition, being insured by Medicare also had a 
statistically significant protective effect (OR=0.27, 95% CI: 0.08, 0.96). The female gender identity also 
had a protective effect against hospitalization during the index ED visit, while age and average SAF score 
did not have statistically significant associations. Age, average SAF score, or being female did not have 
statistically significant associations.  
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Table 3: Logistic Regression Results on Follow-Up Visits and Any Hospitalizations (n=105) 
Dependent Variable Was patient 
hospitalized during 
index ED visit? 
Odds Ratio (95% CI) 
Did patient return to 
hospital within 90 days? 
Odds Ratio (95% CI) 
Combined ED/hospital 
use outcome. 
Odds Ratio (95% CI) 
Treatment (Post-AFib 
Transitions Clinic) 
0.13 (0.05, 0.35)* 6.06 (0.70, 52.13) 0.16 (0.06, 0.42)* 
Average SAF Score 1.62 (0.99, 2.65) 0.71 (0.36, 1.42) 1.53 (0.95, 2.45) 
Female 0.97 (0.35, 2.67) 2.87 (0.65, 12.63) 1.27 (0.48, 3.35) 
Age 1.02 (0.97, 1.06) 1.02 (0.95, 1.09) 1.02 (0.98, 1.06) 
Insured by Medicare 0.27 (0.08, 0.96)* 2.12 (0.26, 16.97) 0.38 (0.11, 1.28) 
Constant 0.97 (0.07, 13.26) 0.00 (0.00, 0.57)* 0.59 (0.05, 7.41) 
*Significant at p<0.05 
Neither treatment status or any of the independent variables had a statistically significant 
association with whether the patient returned to the ED within 90 days of their index ED visit. However, 
though insignificant, treatment patients in the post-period were substantially more likely to return to 
the ED, holding all else equal (OR=60.6, 95% CI: 0.70, 52.13). Figure 3 shows that the small number of 
patients who returned to the ED limits this analysis. Though not statistically significant, patients with 
higher average SAF scores were more likely to return to the ED within 90 days, as might be expected.  
 The third dependent variable reflects overall hospital use by observed patients; that is, the 
patient is coded as 1 if they were hospitalized during their index ED visit, had returned to the ED within 
90 days of index visit, or hospitalized during an observed return visit.  The availability of the AFib 
Transitions Clinic was associated with a substantial reduction in the likelihood of the combined outcome; 
a low- to moderate-risk patient visiting the ED during the post-period was substantially less likely to use 
the hospital or return than a pre-period comparison patient (OR=0.16, 95% CI: 0.06-0.42).  
 The estimated predicted probabilities and marginal effects from the availability of the AFib 
Transitions Clinic on my two dependent variables. Table 4 shows the predicted probabilities and 
marginal effects (estimated difference between the treatment and comparison groups) of the 
availability of the Transitions Clinic visit from the logistic regressions in Table 3. 
16 
 
Table 4: Predicted Probabilities and Marginal Effects of the AFib Transitions Clinic 
 Was patient 
hospitalized during 
index ED visit? 
(95% CI) 
Did patient return to 




 (95% CI) 
Predicted Probability 
Treatment Group 
(Post July 1, 2015) 
32.3% (21.6, 42.9)* 14.2% (6.3, 22.0)* 36.4% (25.3, 47.5)* 
Predicted Probability 
Comparison Group 
(Pre July 1, 2015) 
75.3% (61.1, 89.5)* 2.9% (-2.6, 8.5) 75.7% (61.5, 89.9)* 
Difference in Percentage 
Points 
(Treatment-Comparison) 
-43 (-60.9, -25.1)* 11.3 (1.6, 20.9)* -39.3 (-57.5, -21.2)* 
*Significantly different from zero at p<0.05 
 An AFib patient during the post-period was much less likely to be hospitalized during their index 
visit (32.3% versus 75.3%). Treatment (post-period) patients had an increased likelihood of returning to 
the ED after the index visit relative to the comparison group (14.2% versus the 2.9%). The combined 
outcome shows net benefit of the availability of the Transitions Clinic, with 36.4% of post-period 
patients being hospitalized at the index ED visit or returning to the ED within 90 days versus 75.7% of 
pre-period patients. The estimated marginal effects are all statistically greater than zero, with a 
reduction of 39.3 percentage points for the combined outcome. 
 Table 5 shows the distribution of primary diagnoses among the observed return visits. 
Unfortunately, only 12 observations are available; among these twelve patients, only five of them 
returned due to their AFib, and the others returned for other reasons. Furthermore, only two  
observations occurred during the pre-implementation period (one of them returned for AFib). Further 
research and data collection are needed to better inform the primary reasons for patients returning to 




Table 5: Distribution of Primary Diagnosis Among 12 Patients with Return ED/Hospital Visits 
Primary Diagnosis on Return Visit Within 90 





Atrial Fibrillation 1 4 
Not Atrial Fibrillation 1 6 
 
Discussion 
The analysis supports the effectiveness of the AFib Transitions clinic for its goal of reducing 
hospital use. Specifically, the results are consistent with a substantial reduction in hospital use from a 
disease management clinic and its education program on self-management for patients with AFib. This 
finding is important because of the dearth of research on disease management clinics focused on AFib. 
While it is concerning that the analysis showed that treatment (post-period) patients were more 
likely to return to the ED within 90 days of their index visit, two considerations temper this preliminary 
finding.  First, this study was based on small samples, and the result might not be supported in a larger 
study.  Second, some patients who seem suitable for referral to the AFib Transitions Clinic might need 
additional services to avoid a return to the ED if AFib was the primary reason for return. Therefore, 
additional scrutiny of this important issue using more data is warranted. 
Several other limitations should be considered in addition to the small sample size.  This pilot 
study assessed the experience of one inpatient setting and one clinic, so generalizability could be limited.  
Rather than having a randomized design, the treatment and comparison groups were identified by 
physicians as the type of patient appropriate for the clinic. The sample was predominantly white, and 
the time frame for the study did not allow tracking of outcomes beyond a 90 day follow-up period.  A 
year-long follow-up period can capture returns by patients whose symptoms are not severe enough to 
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require a return within three months.  The observational nature of the data meant that controlling for 
other variables that might affect outcomes was appropriate, but data on potentially important 
characteristics such as income or socio-economic status were not available at all, and data on some 
relevant clinical indicators such as blood pressure were not available. Without a study using a 
randomized design, it is not possible to say with certainty whether the results were directly or strongly 
affected by unmeasured differences between the groups. 
Finally, the large decrease in hospital use (driven by the greater likelihood of discharge without 
hospitalization during the index ED visit) implies that the AFib Transitions Clinic likely reduces the total 
cost of care. Additional data on hospital days and ambulatory visits during the follow-up period could 
enable a cost-effectiveness analysis. Further research is needed to properly estimate the cost-
effectiveness of a disease management clinic targeting patients with AFib emergency visits. 
Conclusion 
 Since this particular clinic is a pilot project, these early findings support efforts by the UNC team 
to replicate the Transitions Clinic at other facilities within the UNC Hospital system or to consider 
initiating a larger randomized trial. Further research is needed to better understand the full impact of 
disease management clinics by getting additional data including a larger sample, additional control 
variables, and more information on implementation and treatment costs of the Transitions Clinic as well 
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